0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lysosomal Storage Diseases Market by Disease Type, Treatment Type, Therapeutic Application, End-User - Global Forecast to 2030- Product Image
Lysosomal Storage Diseases Market by Disease Type, Treatment Type, Therapeutic Application, End-User - Global Forecast to 2030- Product Image
Sale

Lysosomal Storage Diseases Market by Disease Type, Treatment Type, Therapeutic Application, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888909
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The lysosomal storage diseases market is evolving on the strength of scientific advances, increasing collaboration, and strategic investment. As the treatment landscape rapidly transforms, senior decision-makers need actionable intelligence to navigate new industry paradigms, regulatory shifts, and a dynamic competitive arena.

Market Snapshot

The Lysosomal Storage Diseases Market grew from USD 10.17 billion in 2024 to USD 11.01 billion in 2025. It is expected to continue growing at a CAGR of 8.38%, reaching USD 16.49 billion by 2030.

This sector encompasses a diverse set of rare, inherited metabolic disorders, each posing unique clinical and commercial challenges. Growth is fueled by ongoing innovation, new therapeutic modalities, and greater regulatory accommodation for rare diseases. Expanded payer engagement and real-world evidence initiatives are shaping value discussions and patient access worldwide.

Lysosomal Storage Diseases Market: Scope & Segmentation

  • Disease Types: Fabry Disease, Gaucher Disease, Hunter Syndrome, Mucopolysaccharidosis, Niemann-Pick Disease, Pompe Disease.
  • Treatment Types: Enzyme Replacement Therapy (Agalsidase Beta, Alglucerase, Alglucosidase Alfa), Gene Therapy, Hematopoietic Stem Cell Transplant (Allogeneic, Autologous), Substrate Reduction Therapy.
  • Therapeutic Applications: Cardiovascular Involvement, Central Nervous System Involvement, Hematological Disorders, Pulmonary Complications, Skeletal Deformities.
  • End-Users: Academic & Research Institutes, Biopharmaceutical Companies, Hospitals, Specialty Clinics.
  • Regions: United States (including key states), Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland, China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan.
  • Key Companies: Abeona Therapeutics, Alexion Pharmaceuticals, Amicus Therapeutics, ArmaGen, BioMarin Pharmaceutical, CHIESI USA, Denali Therapeutics, Freeline Therapeutics, Homology Medicines, Horizon Pharma, Idorsia Pharmaceuticals, JCR Pharmaceuticals, Neurogene, Novartis, Orchard Therapeutics, Pfizer, Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi, Spark Therapeutics, Swedish Orphan Biovitrum, Takeda Pharmaceutical, Ultragenyx Pharmaceutical, Zevra Therapeutics.

Key Takeaways for Senior Decision-Makers

  • Gene therapies and precision medicine are redefining therapeutic strategies, with the market moving beyond traditional enzyme replacement protocols.
  • Regulatory agencies increasingly support adaptive clinical designs and faster approvals for rare disease therapies, expanding opportunities and accelerating time to market.
  • Collaborative consortia among biopharmaceutical firms, academic institutions, and patient advocacy groups are driving efficient pipeline development and optimizing resource allocation.
  • Digital health integration, AI-driven diagnostics, and real-world evidence capture are strengthening payer engagement and shaping new reimbursement frameworks.
  • Manufacturers are responding to cost pressures and policy volatility by investing in supply chain resilience, including near-shoring production and value-based contracting models.

Impact of Tariff Changes on the U.S. Market

Recent U.S. tariff adjustments are prompting strategic shifts across the supply chain, notably in sourcing, manufacturing, and distribution. Companies are exploring alternative procurement and near-shoring to manage costs, while healthcare providers adjust contracting practices to accommodate tariff-driven pricing dynamics. These market adaptations underscore the importance of robust supply chain strategies and transparent payer negotiations in ensuring continuous patient access.

Methodology & Data Sources

This report is grounded in a multi-stage research approach, beginning with a comprehensive literature review and database analysis. Key data points were validated through in-depth interviews with clinicians, executives, and advocacy leaders. All insights underwent meticulous triangulation and review by industry advisors to ensure the highest level of precision and relevance.

Lysosomal Storage Diseases Market: Why This Report Matters

  • Enables portfolio managers and strategic leaders to prioritize investments based on actionable, region-specific insights and pipeline developments.
  • Supports pricing, access, and partnership decisions with validated data and forward-looking forecasts tailored to payer and policy trends.

Conclusion

The lysosomal storage diseases market is reshaping itself amid rapid advances in therapeutics, collaborative models, and policy adaptation. Decision-makers equipped with this comprehensive intelligence can confidently guide strategic action and secure sustainable growth in this transformative era.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lysosomal Storage Diseases Market, by Disease Type
8.1. Introduction
8.2. Fabry Disease
8.3. Gaucher Disease
8.4. Hunter Syndrome
8.5. Mucopolysaccharidosis
8.6. Niemann-Pick Disease
8.7. Pompe Disease
9. Lysosomal Storage Diseases Market, by Treatment Type
9.1. Introduction
9.2. Enzyme Replacement Therapy
9.2.1. Agalsidase Beta
9.2.2. Alglucerase
9.2.3. Alglucosidase Alfa
9.3. Gene Therapy
9.4. Hematopoietic Stem Cell Transplant
9.4.1. Allogeneic Transplant
9.4.2. Autologous Transplant
9.5. Substrate Reduction Therapy
10. Lysosomal Storage Diseases Market, by Therapeutic Application
10.1. Introduction
10.2. Cardiovascular Involvement
10.3. Central Nervous System Involvement
10.4. Hematological Disorders
10.5. Pulmonary Complications
10.6. Skeletal Deformities
11. Lysosomal Storage Diseases Market, by End-User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Biopharmaceutical Companies
11.4. Hospitals
11.5. Specialty Clinics
12. Americas Lysosomal Storage Diseases Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Lysosomal Storage Diseases Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Lysosomal Storage Diseases Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Abeona Therapeutics Inc.
15.3.2. Alexion Pharmaceuticals, Inc.
15.3.3. Amicus Therapeutics,Inc.
15.3.4. ArmaGen, Inc.
15.3.5. BioMarin Pharmaceutical, Inc.
15.3.6. CHIESI USA, Inc.
15.3.7. Denali Therapeutics Inc.
15.3.8. Freeline Therapeutics
15.3.9. Homology Medicines, Inc.
15.3.10. Horizon Pharma PLC
15.3.11. Idorsia Pharmaceuticals Ltd.
15.3.12. JCR Pharmaceuticals Co., Ltd.
15.3.13. Neurogene Inc.
15.3.14. Novartis AG
15.3.15. Orchard Therapeutics Limited
15.3.16. Pfizer Inc.
15.3.17. Protalix Biotherapeutics Inc.
15.3.18. Sangamo Therapeutics, Inc.
15.3.19. Sanofi S.A.
15.3.20. Spark Therapeutics, Inc.
15.3.21. Swedish Orphan Biovitrum AB
15.3.22. Takeda Pharmaceutical Company Limited
15.3.23. Ultragenyx Pharmaceutical Inc.
15.3.24. Zevra Therapeutics,Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET MULTI-CURRENCY
FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET MULTI-LANGUAGE
FIGURE 3. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HUNTER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY NIEMANN-PICK DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY AGALSIDASE BETA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALGLUCERASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CARDIOVASCULAR INVOLVEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM INVOLVEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY PULMONARY COMPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SKELETAL DEFORMITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 53. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 54. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 59. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 60. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 90. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 91. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 94. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 96. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 97. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 108. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 109. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 112. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 114. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 115. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 120. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 121. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 138. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 139. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 148. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 150. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 151. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 156. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 157. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 160. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 162. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 163. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 172. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 174. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 175. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 178. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 180. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 181. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 192. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 193. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 196. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 198. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 199. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 204. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 205. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 214. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 215. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 216. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 217. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 218. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 221. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 223. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 224. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 227. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 229. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 230. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 251. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 253. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 254. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 286. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
TABLE 287. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Sample File DOWNLOAD NOW

Companies Mentioned

The companies profiled in this Lysosomal Storage Diseases market report include:
  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics,Inc.
  • ArmaGen, Inc.
  • BioMarin Pharmaceutical, Inc.
  • CHIESI USA, Inc.
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Homology Medicines, Inc.
  • Horizon Pharma PLC
  • Idorsia Pharmaceuticals Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics Limited
  • Pfizer Inc.
  • Protalix Biotherapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
  • Zevra Therapeutics,Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.01 Billion
Forecasted Market Value ( USD ) by 2030 $ 16.49 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Lysosomal Storage Diseases - Global Strategic Business Report - Product Image

Lysosomal Storage Diseases - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
EUR$5,850USDGBP
Lysosomal Storage Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Lysosomal Storage Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Lysosomal Disease Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Lysosomal Disease Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
EUR$3,250USDGBP
EUR$4,850USDGBP
Lysosomal Disease Treatment Market Report 2025 - Product Image

Lysosomal Disease Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Lysosomal Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Lysosomal Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more